Major histocompatibility complex class I and class II molecule-mediated tumor antigen presentation (MHC-I/II antigen presentation)

The term refers to the **process** by which peptides derived from proteins are presented on the cell surface by major histocompatibility complex (MHC) class I and class II molecules[1][4][6]. MHC class I molecules display peptides from endogenous (intracellular) proteins to cytotoxic CD8+ T cells, while MHC class II molecules present peptides from exogenous (extracellular) proteins to helper CD4+ T cells[3][4][6]. This antigen presentation is vital for immune surveillance and the activation of adaptive immunity, including tumor recognition and destruction. Expression of MHC class I is found on nearly all nucleated cells, whereas MHC class II is largely restricted to antigen-presenting cells such as dendritic cells, macrophages, and B cells[1][4]. Tumors can evade immune detection by altering or reducing their MHC expression, which can lead to immune escape and impact the efficacy of immunotherapies[2][7]. Notes on terminology and correctness: - "Tumor antigen presentation via major histocompatibility complex class I/II molecules" is **not a single protein or receptor**, but an immunological process involving multiple proteins (MHC class I/II, TAP, proteasome, etc.)[6][7]. - Therapeutic targeting is usually directed at modulating this pathway or at the MHC molecules themselves, not at "tumor antigen presentation" as a single entity. - The most appropriate canonical names would be "Major histocompatibility complex class I molecule" (HLA-I) or "Major histocompatibility complex class II molecule" (HLA-II), depending on the context[1][4][6]. Summary: This entry represents a **function/process** (antigen presentation) rather than a discrete molecular target, so is_incorrect is true for it being a conventional drug target. For structuring, break out into either MHC class I molecule or MHC class II molecule as more specific targets.

Other names

MHC-mediated antigen presentationMHC antigen presentation pathwayantigen presentation via MHCMHC-I/II antigen presentation